Clinical Trial Update: Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Triiodothyronine (T3) supplementation for major depressive disorder and bipolar disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Drugs mentioned

• Triiodothyronine (liothyronine sodium)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Major Depression, Bipolar Disorder | Phase 3 | Status: COMPLETED